140 related articles for article (PubMed ID: 27042072)
1. No association between BDNF Val66Met polymorphism and treatment response in obsessive-compulsive disorder in the Japanese population.
Umehara H; Numata S; Kinoshita M; Watanabe S; Nakaaki S; Sumitani S; Ohmori T
Neuropsychiatr Dis Treat; 2016; 12():611-5. PubMed ID: 27042072
[TBL] [Abstract][Full Text] [Related]
2. Brain-derived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorder.
Tükel R; Gürvit H; Ozata B; Oztürk N; Ertekin BA; Ertekin E; Baran B; Kalem SA; Büyükgök D; Direskeneli GS
Am J Med Genet B Neuropsychiatr Genet; 2012 Oct; 159B(7):850-8. PubMed ID: 22911909
[TBL] [Abstract][Full Text] [Related]
3. The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls.
Shang Y; Wang N; Zhang E; Liu Q; Li H; Zhao X
Front Psychiatry; 2021; 12():685041. PubMed ID: 35095581
[No Abstract] [Full Text] [Related]
4. Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.
Harika-Germaneau G; Langbour N; Patri S; Solinas M; Chatard A; Millet B; Hashemian F; Pérault-Pochat MC; Jaafari N; Lafay-Chebassier C
CNS Spectr; 2022 Oct; 27(5):645-651. PubMed ID: 34313207
[TBL] [Abstract][Full Text] [Related]
5. Is Brain-Derived Neurotrophic Factor (BDNF) Val66Met Polymorphism Associated with Obsessive-Compulsive Disorder? A Meta-Analysis.
Wang S; Xu X; Yan P; Song M; Li J; Wang S
Psychiatr Danub; 2019 Jun; 31(2):141-147. PubMed ID: 31291217
[TBL] [Abstract][Full Text] [Related]
6. BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder.
Wang Y; Zhang H; Li Y; Wang Z; Fan Q; Yu S; Lin Z; Xiao Z
J Affect Disord; 2015 Nov; 186():7-12. PubMed ID: 26209750
[TBL] [Abstract][Full Text] [Related]
7. The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD).
Katerberg H; Lochner C; Cath DC; de Jonge P; Bochdanovits Z; Moolman-Smook JC; Hemmings SM; Carey PD; Stein DJ; Sondervan D; Boer JA; van Balkom AJ; Polman A; Heutink P
Am J Med Genet B Neuropsychiatr Genet; 2009 Dec; 150B(8):1050-62. PubMed ID: 19219856
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the association of brain-derived neurotrophic factor Val66Met polymorphism with obsessive-compulsive disorder.
Wang J; Zhang F; Zhu W; Liu Y; Zhou Z
Acta Neuropsychiatr; 2015 Dec; 27(6):327-35. PubMed ID: 26503495
[TBL] [Abstract][Full Text] [Related]
9. No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients.
Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Hayashi K; Iwata N; Nakamura J
Clin Psychopharmacol Neurosci; 2012 Apr; 10(1):49-53. PubMed ID: 23429762
[TBL] [Abstract][Full Text] [Related]
10. Do obsessive-compulsive disorder and Tourette syndrome share a common susceptibility gene? An association study of the BDNF Val66Met polymorphism in the Chinese Han population.
Liu S; Cui J; Niu Z; Yi M; Zhang X; Che F; Ma X
World J Biol Psychiatry; 2015; 16(8):602-9. PubMed ID: 25771937
[TBL] [Abstract][Full Text] [Related]
11. Association study between BDNF gene variants and Mexican patients with obsessive-compulsive disorder.
Márquez L; Camarena B; Hernández S; Lóyzaga C; Vargas L; Nicolini H
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1600-5. PubMed ID: 23999029
[TBL] [Abstract][Full Text] [Related]
12. BDNF gene and obsessive compulsive disorder risk, symptom dimensions and treatment response.
Taj M J RJ; Ganesh S; Shukla T; Deolankar S; Nadella RK; Sen S; Purushottam M; Reddy YCJ; Jain S; Viswanath B
Asian J Psychiatr; 2018 Dec; 38():65-69. PubMed ID: 29079096
[TBL] [Abstract][Full Text] [Related]
13. Serum brain-derived neurotrophic factor, Val66Met polymorphism and open-label SSRI treatment response in Major Depressive Disorder.
Smit AJT; Wu GWY; Rampersaud R; Reus VI; Wolkowitz OM; Mellon SH
Psychoneuroendocrinology; 2024 Jul; 165():107045. PubMed ID: 38636352
[TBL] [Abstract][Full Text] [Related]
14. BDNF Val66Met modifies the risk of childhood trauma on obsessive-compulsive disorder.
Hemmings SM; Lochner C; van der Merwe L; Cath DC; Seedat S; Stein DJ
J Psychiatr Res; 2013 Dec; 47(12):1857-63. PubMed ID: 24050777
[TBL] [Abstract][Full Text] [Related]
15. Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients.
Hashim HM; Fawzy N; Fawzi MM; Karam RA
J Psychiatr Res; 2012 Jun; 46(6):762-6. PubMed ID: 22521161
[TBL] [Abstract][Full Text] [Related]
16. Investigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD).
Hemmings SM; Kinnear CJ; Van der Merwe L; Lochner C; Corfield VA; Moolman-Smook JC; Stein DJ
World J Biol Psychiatry; 2008; 9(2):126-34. PubMed ID: 17853300
[TBL] [Abstract][Full Text] [Related]
17. The relationship between the Met allele of the BDNF Val66Met polymorphism and impairments in decision making under ambiguity in patients with obsessive-compulsive disorder.
da Rocha FF; Malloy-Diniz L; Lage NV; Corrêa H
Genes Brain Behav; 2011 Jul; 10(5):523-9. PubMed ID: 21401876
[TBL] [Abstract][Full Text] [Related]
18. Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder.
Fullana MA; Alonso P; Gratacòs M; Jaurrieta N; Jiménez-Murcia S; Segalàs C; Real E; Estivill X; Menchón JM
Eur Psychiatry; 2012 Jul; 27(5):386-90. PubMed ID: 22153732
[TBL] [Abstract][Full Text] [Related]
19. No association between the COMT Val158Met polymorphism and the long-term clinical response in obsessive-compulsive disorder in the Japanese population.
Umehara H; Numata S; Tajima A; Kinoshita M; Nakaaki S; Imoto I; Sumitani S; Ohmori T
Hum Psychopharmacol; 2015 Sep; 30(5):372-6. PubMed ID: 26010653
[TBL] [Abstract][Full Text] [Related]
20. BDNF association study with obsessive-compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients.
Abdolhosseinzadeh S; Alizadeh N; Shams J; Asadi S; Ahmadiani A
Exp Clin Psychopharmacol; 2020 Apr; 28(2):216-224. PubMed ID: 31180700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
